Abstract
Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Current Drug Targets
Title: Ketamine: New Indications for an Old Drug
Volume: 6 Issue: 7
Author(s): M. G. Annetta, D. Iemma, C. Garisto, C. Tafani and R. Proietti
Affiliation:
Keywords: ketamine, analgesia, opioids
Abstract: Ketamine is a non-competitive antagonist to the phencyclidine site of N-methyl-d-aspartate (NMDA) receptor for glutamate, though its effects are mediated by interaction with many others receptors. It has been introduced in clinical use since 1960s but today it is not largely employed as a general anaesthetic for its undesired psychic effects (emergence reactions) occurring in approximately 12% of patients. In the last decade, there has been a renewed interest in the use of subanaesthetic doses of ketamine for the treatment of acute and chronic pain. In the late 1990s, multiple prospective, randomised, controlled study has shown the efficacy of low dose of ketamine for postoperative pain relief, for analgesia during regional or local anaesthesia, and for opioid-sparing effect. At present, non-definitive conclusion can be drawn. More data are needed to define the possible long term effects and the clinical goal of ketamine use.
Export Options
About this article
Cite this article as:
Annetta G. M., Iemma D., Garisto C., Tafani C. and Proietti R., Ketamine: New Indications for an Old Drug, Current Drug Targets 2005; 6 (7) . https://dx.doi.org/10.2174/138945005774574533
DOI https://dx.doi.org/10.2174/138945005774574533 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Valproate and Valproate-Analogues: Potent Tools to Fight Against Cancer
Current Medicinal Chemistry Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Antiepileptic Drugs for Preventing Seizures in Patients with Chronic Subdural Hematoma
Current Pharmaceutical Design 2,4,5-Trisubstituted Thiazole: A Privileged Scaffold in Drug Design and Activity Improvement
Current Topics in Medicinal Chemistry Application of MicroPET in Basic Epilepsy Research
Current Medical Imaging Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
Current Pharmaceutical Design Therapeutic Potential of Neurogenesis for Prevention and Recovery from Alzheimers Disease: Allopregnanolone as a Proof of Concept Neurogenic Agent
Current Alzheimer Research Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Editorial
Recent Patents on CNS Drug Discovery (Discontinued) Chronic Stress Impacts on Olfactory System
CNS & Neurological Disorders - Drug Targets Is Mania the Hypertension of the Mood? Discussion of A Hypothesis
Current Neuropharmacology The Metabolic Basis for Nervous System Dysfunction in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease
Current Neurovascular Research Evaluation of Anticonvulsant Activity and Toxicity Screening of Semicarbazones Derived from Quinazolinone Scaffold
Current Bioactive Compounds Animal Models of Maternal Immune Activation in Depression Research
Current Neuropharmacology Patent Selections
Recent Patents on DNA & Gene Sequences Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Current Alzheimer Research Review of the Biological Activity of Maslinic Acid
Current Drug Targets